MediSieve, a London based biotech startup, has been busy presenting and demonstrating its technology to some of the world's leading investors throughout March.

MediSieve was a presenting company at the virtual 15th Annual European Life Sciences CEO Forum (ELSF) that took place on the 1st-2nd of March. The ELSF is part of Sachs Spring Life Sciences Week which also incorporates the 3rd Annual European HealthTech CEO Forum. This global bio-pharma industry event addressed the main challenges for 2022, including investment, partnering and alliance management. The speakers contributed their insights in panels which covered the macro picture as well as innovation in different therapeutic sectors. The first day focused on Bio Capital & Investment, whilst the second looked at Bio-Pharma Partnering & Therapeutics. Apart from presenting MediSieve's technology, its Founder and CEO, Dr George Frodsham, sat at the Platform Technologies & Novel Therapeutics expert panel and has said that

"It was a real honour to be alongside such esteemed speakers on the panel. The discussion was very interesting and I learnt a lot from the insights of the other panelists. I hope that the discussion was useful for those who watched it, and am looking forward to doing more!"

MediSieve also participated in the MedCity's Pitching Days, which included an online pitching day in February and was followed up by an in-person investor networking event on the 9th of March. The Medcity's Investment Hub featured carefully selected start-ups and university spinouts from across the life sciences industry. MediSieve presented its business and products in person to a select group of Investors alongside other 4 early-stage companies, that have a direct or indirect impact on patients. The event has allowed the company to network and connect with similar business as well as investors. MediSieve is grateful to be part of such a resourceful community.

The company finished off the month by presenting at the MedInvest Pharmaceutical and Biotechnology Investor Conference on the 30-31st of March. MedInvest Conferences are a leading conference series in Healthcare and Life Sciences. The conferences are conducted four times a year, typically focusing on specific indications: oncology, cardiology, neurology, etc. The latest conference focused on drug development and delivery as well as biotech tools and therapies across multiple indications. Dr George Frodsham discussed the latest trends in drug discovery, clinical trials, and market opportunity, exploring new frontiers for business and for healthcare in pharma and biotech alongside other Global Leaders in the Industry. The events featured two days of livestreams with company presentations, keynote talks, and panel discussions as well as four days of one-on-one meetings. The conference hosted companies specializing in drug development and delivery as well as biotech and therapeutics across many indications: oncology, immunology, neurology, cardiology, diabetes, infectious diseases, pulmonary diseases, autoimmune diseases, dermatology, and many others. George has commented that

"It was great to be part of the conference. I enjoyed pitching MediSieve and hopefully it helped our message get out to more people. We were pleased to connect with a number of investors and look forward to continuing those conversations."

MediSieve is delighted to be recognised and invited to such events and panels and hopes to get even more opportunities to talk about its technology as well as network with fellow startups and investors! 

More about ELSF event:

https://www.sachsforum.com/15elsf-about.html

More about MedCity's Pitching Days:

https://www.medcityhq.com/events/medcity-investment-hub-annual-event-schedule-save-the-dates-and-submit-decks-by-deadlines/

More about MedInvest:

https://www.medinvestconferences.com

Any future events and where to meet the company an be found here:

https://www.medisieve.com/News-Events/Events

About MediSieve

MediSieve is a biotech company, that has developed “Magnetic Haemofiltration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From pancreatitis to malaria to leukaemia and viral infections, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk

Sort by: Newest First Oldest First Most Popular Most unliked